Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transfluvac: H1N1 Vaccine in Renal Transplant Recipients
NCT01086904Phase 2Completed
- Sponsor
- Inserm
- Start
- Nov 2009
- Primary completion
- Jan 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of inactivated non-adjuvanted pandemic H1N1 vaccine in influenza A H1N1 infection (H1N1), sponsored by Inserm. Primary endpoint: Seroprotection Rate at 42 days. Started Nov 2009; status: completed.
02
Drugs
inactivated non-adjuvanted pandemic H1N1 vaccine
03
Conditions
influenza A H1N1 infection (H1N1)
Beyond the preview
Go deeper on NCT01086904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01086904.